Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 2008 August 1; 118(8): 2722–2732.
Published online 2008 July 10. doi:  10.1172/JCI33713
PMCID: PMC2447925

Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression


TGF-β and its signaling mediators, Smad2, -3, and -4, are involved with tumor suppression and promotion functions. Smad4–/– mouse epidermis develops spontaneous skin squamous cell carcinomas (SCCs), and Smad3–/– mice are resistant to carcinogen-induced skin cancer; however, the role of Smad2 in skin carcinogenesis has not been explored. In the present study, we found that Smad2 and Smad4, but not Smad3, were frequently lost in human SCCs. Mice with keratinocyte-specific Smad2 deletion exhibited accelerated formation and malignant progression of chemically induced skin tumors compared with WT mice. Consistent with the loss of Smad2 in poorly differentiated human SCCs, Smad2–/– tumors were poorly differentiated and underwent epithelial-mesenchymal transition (EMT) prior to spontaneous Smad4 loss. Reduced E-cadherin and activation of its transcriptional repressor Snail were also found in Smad2–/– mouse epidermis and occurred more frequently in Smad2-negative human SCCs than in Smad2-positive SCCs. Knocking down Snail abrogated Smad2 loss–associated EMT, suggesting that Snail upregulation is a major mediator of Smad2 loss–associated EMT. Furthermore, Smad2 loss led to a significant increase in Smad4 binding to the Snail promoter, and knocking down either Smad3 or Smad4 in keratinocytes abrogated Smad2 loss–associated Snail overexpression. Our data suggest that enhanced Smad3/Smad4-mediated Snail transcription contributed to Smad2 loss–associated EMT during skin carcinogenesis.


TGF-β signaling is involved in tissue homeostasis and cancer development (1). Ligand binding to heteromers of TGF-β type I and type II receptors (TGF-βRI and TGF-βRII) induces TGF-βRI to phosphorylate Smad2 and Smad3. Phosphorylated Smad2 and Smad3 bind a co-Smad, Smad4, and the heteromeric Smad complexes translocate into the nucleus to regulate transcription of TGF-β target genes (1). Smad3 binds to the Smad-binding element (SBE) of a target gene, and subsequently recruits Smad4 to the same SBE. Smad2 does not bind to DNA directly but complexes with Smad3 and Smad4 as either a coactivator or a corepressor for Smad3 and Smad4 (2). Each of these Smads has been implicated by in vitro studies in mediating the multiple functions of TGF-β (3). However, increasing numbers of studies show that Smad2, -3, and -4 are regulated differently and exhibit distinct physiological functions in vivo (2, 3). For instance, both Smad2- and Smad4-knockout mice are embryonic lethal due to failure in embryonic axis patterning and endoderm specification (4) and failure of proper endoderm and mesoderm formation (5), respectively. In contrast, Smad3-knockout mice are viable but succumb to mucosal immunity defects after birth (6).

In many cancer types, TGF-β signaling has a tumor suppressive effect early in carcinogenesis but promotes invasion and metastasis at later stages (7). Increasing evidence suggests that Smads mediate both tumor suppression and promotion functions of TGF-β. In epithelial cells, Smad2, -3, and -4 are involved in growth inhibition (2), a major tumor suppressive effect of TGF-β, and epithelial-mesenchymal transition (EMT) (8, 9), an early and major tumor promoting effect of TGF-β. However, genes associated with each of these biological processes are differentially regulated by individual Smads (1, 3). Loss of Smad2 or Smad4 at the genetic and protein levels has been widely reported in various cancer types (2, 10). In contrast, Smad3 mutation is found only in colon cancer at a very low frequency (11), and Smad3 protein loss was reported only in pediatric T cell acute lymphoblastic leukemia (12). In human skin cancer, individual Smad expression patterns in squamous cell carcinomas (SCCs) have not been documented. The roles of individual Smads in skin carcinogenesis have been assessed mainly through genetically engineered mouse models. Smad4 deletion in keratinocytes results in spontaneous SCC formation (13, 14), indicating a dominant tumor suppressive effect of Smad4 in skin carcinogenesis. Smad3-null keratinocytes transduced with a v-ras oncogene exhibited increased malignancy when grafted to immune-compromised mouse skin (15). However, Smad3-knockout mice are resistant to skin chemical carcinogenesis (16, 17) due to abrogation of TGF-β1-mediated inflammation and gene expression critical for tumor promotion (17). The role of Smad2 in skin carcinogenesis has not been fully explored in animal models as germline Smad2-knockout mice die in early embryogenesis (4). In the current study, we assessed the role and molecular mechanisms of Smad2 in skin carcinogenesis.


Smad2 and Smad4 were frequently lost in human skin SCCs.

We examined Smad2 expression patterns by immunohistochemistry (IHC) in 83 human skin SCCs. Smad3, a Smad2 signaling partner, and co-Smad, Smad4, were also examined. In comparison with the epidermis in normal skin, Smad2 and Smad4 each were lost in 70% of skin SCC samples, whereas Smad3 loss was only seen in 5% of cases (Table (Table11 and Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI33713DS1). Additionally, the incidence of Smad2 loss occurred in 100% of poorly differentiated SCCs, which was significantly higher than Smad4 loss in poorly differentiated SCCs (P = 0.005; Table Table1). 1).

Table 1
Proteins of Smad2 and Smad4, but not Smad3, were lost in human skin SCCs

To determine whether loss of Smad2 and Smad4 proteins in human skin cancer occurs at the pretranslational level, we examined mRNA levels of Smad2 and Smad4 from 33 cases of poorly differentiated human SCCs and 6 normal skin samples. In comparison with control skin, 31/33 (94%) of human skin SCC samples showed at least a 50% reduction of Smad2 mRNA, and 28/33 (85%) of these samples showed at least a 50% reduction of Smad4 mRNA (Figure (Figure1A).1A). Such high rates of Smad2 and Smad4 loss at the mRNA level prompted us to examine if they are lost at the genetic level. Among samples with more than 50% mRNA reduction of Smad2 and Smad4, 21 samples contained adjacent nonneoplastic skin in their paraffin sections. We dissected the adjacent nonneoplastic skin in each section as a control for each tumor sample and performed a loss of heterozygosity (LOH) analysis for Smad2 and Smad4 (Figure (Figure1B1B and Supplemental Figure 2). We found that 14 samples (67%) exhibited LOH at the Smad2 locus, and 12 samples (57%) exhibited LOH at the Smad4 locus. A total of 17 samples (81%) had LOH at either the Smad2 or Smad4 locus.

Figure 1
Reduced mRNA and LOH of Smad2 and Smad4 in human skin SCCs.

Keratinocyte-specific Smad2 deletion resulted in increased susceptibility to skin carcinogenesis.

Our previous study has revealed that Smad4 loss in keratinocytes results in spontaneous skin SCCs (14). To determine if the high incidence of Smad2 loss in human skin SCCs also plays a causal role in skin carcinogenesis, we generated keratinocyte-specific Smad2-knockout mice (Supplemental Figure 3). Mice with RU486-controlled Cre recombinase targeted by a keratin 5 (K5) promoter (K5.Cre*PR1) were generated as previously reported (18). We mated K5.Cre*PR1 mice with Smad2 floxed mice (Smad2f/f) (19). Smad2 deletion in keratinocytes was achieved by topical application of RU486. Unlike Smad4–/– epidermis, Smad2–/– mice did not develop spontaneous tumors within 18 months. To further assess whether Smad2 loss alters susceptibility to skin carcinogenesis, we applied a 2-stage chemical carcinogenesis protocol, which gives discrete stages of benign papillomas and malignant SCCs in normal mice (17). Littermates from K5.Cre*PR1 and Smad2f/f breeding were divided by their genotypes (K5.Cre*PR1/Smad2f/f for K5.Smad2–/–; K5.Cre*PR1/Smad2f/wt for K5.Smad2+/–; K5.Cre*PR1, Smad2f/f, and Smad2f/wt for Smad2+/+) and treated with 20 μg RU486 daily for 5 days at 6 weeks of age to induce Smad2 gene deletion in keratinocytes. Two weeks after RU486 treatment, when keratinocytes in the entire epidermis were expected to be replaced with Smad2–/– or Smad2+/– epidermal stem cells in K5.Cre*PR1/Smad2f/f or K5.Cre*PR1/Smad2f/wt mice, respectively, we topically applied a subcarcinogenic dose of dimethylbenz[α]anthracene (DMBA, 20 μg/mouse). One week later, we began to topically apply 12-O-tetradecanoyl-phorbol-13-acetate (TPA, 5 μg/mouse) twice a week for 20 weeks. K5.Smad2–/– and K5.Smad2+/– mice developed tumors faster and had 2- to 3-fold more tumors per mouse than Smad2+/+ mice (P < 0.001; Figure Figure2A).2A). Malignant conversion was also accelerated in K5.Smad2–/– and K5.Smad2+/– mice (P < 0.05 compared with Smad2+/+ mice). Notably, at each time point, more K5.Smad2–/– and K5.Smad2+/– mice developed SCCs than Smad2+/+ mice (Figure (Figure2B).2B). These results indicate Smad2-deficient epidermis is more susceptible to skin tumor formation and malignant conversion.

Figure 2
Accelerated tumor formation and malignant conversion of skin carcinogenesis in K5.Smad2-knockout mice.

Because K5.Smad2+/– also exhibited accelerated tumor formation and malignant progression similar to K5.Smad2–/– mice, we examined endogenous Smad2 levels in K5.Smad2+/– tumors. Smad2 protein was still detectable in all K5.Smad2+/– papillomas but was lost in 60% cases of K5.Smad2+/– SCCs (Supplemental Figure 4). At this stage, approximately 45% SCC cases from Smad2+/+ mice also lost Smad2 protein as determined by Smad2 antibody staining (Supplemental Figure 4; P < 0.05). These data suggest haploid insufficiency of Smad2+/– keratinocytes at early stages of skin carcinogenesis, and spontaneous Smad2 protein loss from the remaining allele in SCCs caused them to progress to malignancy, similar to Smad2–/– SCCs.

K5.Smad2–/– tumors were poorly differentiated and exhibited an increase in EMT.

To determine whether accelerated skin carcinogenesis in K5.Smad2–/– mice was a result of abrogating TGF-β-induced growth inhibition and/or apoptosis, we evaluated cell proliferation via BrdU incorporation and apoptosis via the TUNEL assay. Apoptosis in K5.Smad2–/– nonlesional and tumor tissues did not differ from those in K5.Smad2+/+ controls (data not shown). Although nonlesional K5.Smad2–/– skin did not show increased proliferation, TPA-treated K5.Smad2–/– skin exhibited increased proliferation and epidermal hyperplasia (Supplemental Figure 5). However, proliferation rates became comparable in tumors between K5.Smad2–/– and WT mice (data not shown). Histological analyses revealed that K5.Smad2–/– tumors were generally poorly differentiated. The earliest K5.Smad2–/– papillomas lacked stratified epithelial structure (Figure (Figure2C)2C) and exhibited loss of loricrin and filaggrin, which are terminal differentiation markers (data not shown), and K1, an early differentiation marker (Figure (Figure2C),2C), but expressed K8 (Figure (Figure2C),2C), a marker of simple epithelia that is not expressed in stratified epithelia but is usually expressed in late-stage SCCs (20). In contrast, papillomas in WT mice showed partial or complete loss of loricrin and filaggrin (data not shown), without K8 expression, but retained uniform K1 expression (Figure (Figure2C).2C). At the SCC stage, K5.Smad2–/– SCCs were poorly differentiated and often showed clusters of cells that underwent EMT (Figure (Figure2C),2C), whereas most SCCs from WT mice were well differentiated (Figure (Figure2C).2C). While only 1 out of 20 WT mice developed an EMT-type of spindle cell carcinoma (SPCC) 50 weeks after TPA promotion, K5.Smad2+/– and K5.Smad2–/– mice developed more SPCCs at earlier time points (3 out of 12 K5.Smad2+/– and 5 out of 19 K5.Smad2–/– starting at 27–35 weeks).

K5.Smad2–/– tumors exhibited pathological alterations associated with EMT.

The poorly differentiated nature of Smad2–/– tumors prompted us to examine the status of E-cadherin, an adhesion molecule critical for maintaining epithelial structure. While E-cadherin was lost in only patchy areas of late-stage Smad2+/+ papillomas, Smad2–/– papillomas exhibited nearly complete loss of E-cadherin (Figure (Figure3).3). In contrast, early stage Smad4–/– spontaneous SCCs retained membrane-associated E-cadherin in most tumor cells (Figure (Figure3).3). We then examined expression patterns of Snail, a transcriptional repressor of E-cadherin (21). Snail antibody staining, which recognizes both Snail and Slug, revealed a patchy, cytoplasmic staining pattern in WT papillomas and early stage Smad4–/– spontaneous SCCs (Figure (Figure3).3). In contrast, Smad2–/– tumors exhibited strong Snail staining primarily in the nucleus (Figure (Figure3).3). Both chemically induced WT SCCs and Smad4–/– spontaneous SCCs showed reduced E-cadherin and increased Snail nuclear staining in late stages, approximately 10–20 weeks after SCC formation (data not shown). K5.Smad2–/– tumors also showed an increase in mesenchymal markers, vimentin and αSMA (Supplemental Figure 6A), which are associated with motility and invasiveness (22, 23). These markers were restricted to the stroma of K5.Smad2+/+ papillomas and spontaneous Smad4–/– SCCs but were detected in both tumor epithelia and stroma of K5.Smad2–/– papillomas. Additionally, vimentin and αSMA were present in the hyperplastic epidermis adjacent to papillomas of K5.Smad2–/– mice (Supplemental Figure 6B), suggesting that EMT is a relatively early event in K5.Smad2–/– carcinogenesis. We then examined if the EMT phenotype occurs in K5.Smad2–/– without exposure to a carcinogen. Seventy-two hours after Smad2 was deleted in neonatal skin, a marked loss of E-cadherin and an associated increase in nuclear Snail were seen in Smad2–/– epidermis and hair follicles when compared with RU486-treated WT and K5.Smad4–/– skin (Figure (Figure3B).3B). However, vimentin and αSMA were not detected in K5.Smad2–/– epidermis (data not shown). These results suggest that EMT is an early effect of Smad2 loss, and additional insults during carcinogenesis further enhanced Smad2 loss–associated EMT phenotype.

Figure 3
Snail activation and E-cadherin (ECad) loss in K5.Smad2–/– tissues.

Smad2 loss resulted in molecular alterations of TGF-β target genes associated with EMT.

To assess if Smad2 loss–associated EMT was associated with increased TGF-β1 ligand, which plays an important role in EMT (24), we examined TGF-β1 levels in WT and Smad2–/– skin and tumors. We found neither elevated TGF-β1 nor alterations of Smad3 and Smad4 in K5.Smad2–/– skin and papillomas in comparison with WT controls (data not shown). Elevated TGF-β1 protein was found in WT and K5.Smad2–/– SCCs at comparable levels (Supplemental Figure 7). Consistent with this data, western analyses showed that in comparison with WT tumors, K5.Smad2–/– tumors did not have increased levels of pJNK, pERK, and pMAPK (data not shown), the major non-Smad pathways of TGF-β–induced EMT that require a higher level of TGF-β1 than that found in WT tumors (25). Consistent with our previous observation that approximately 30%–40% of chemically induced SCC cases exhibited reduction in Smad3 and Smad4 at late stages (26), both WT and K5.Smad2–/– SCCs showed reduced Smad3 and Smad4 in approximately 40% of cases (data not shown). SCCs that retained Smad3 showed similar patterns between WT and K5.Smad2–/– mice (Supplemental Figure 7). K5.Smad2–/– SCCs that retained Smad4 showed more nuclear staining than K5.Smad2+/+ SCCs (Supplemental Figure 7). To further determine whether changes in EMT-associated proteins are the result of transcriptional deregulation of these genes by Smad2 loss, we examined mRNA levels of these molecules in K5.Smad2–/– and K5.Smad2+/+ papillomas, at the stage prior to the pathological appearance of EMT cells in K5.Smad2–/– tumors. Transcripts of K8, Snail, Slug, vimentin, and tenascin C were all significantly upregulated in K5.Smad2–/– papillomas in comparison with WT papillomas (Figure (Figure4A).4A). In contrast, transcripts of E-cadherin were downregulated in Smad2–/– papillomas in comparison with WT controls (Figure (Figure4B).4B). Further, increased transcripts of Snail and Slug and decreased E-cadherin transcripts were also detected in day 3 K5.Smad2–/– skin in comparison with WT skin (Figure (Figure4,4, C and D). No changes in expression levels of vimentin and tenascin C were observed in K5.Smad2–/– skin (data not shown). These data suggest that upregulation of Snail and/or Slug and the subsequent E-cadherin reduction represent an early effect of Smad2 loss in keratinocytes.

Figure 4
Altered gene expression associated with dedifferentiation and EMT in K5.Smad2–/– papillomas and epidermis.

To assess if Smad2 regulates Snail and Slug differently from Smad3 and Smad4 in keratinocytes, we examined expression levels of Snail and Slug in cultured human HaCaT keratinocytes after knocking down Smad2, -3, or -4. After 48 to 72 hours of transfection of HaCaT cells with siRNAs for Smad2, -3, or -4, the respective mRNA levels were reduced by at least 70% (Supplemental Figure 8). In mock-transfected cells, increased Snail mRNA was detected after 1 hour of TGF-β1 treatment and remained increased for 48 hours (data not shown), with a 9-fold increase at 2 hours (Figure (Figure4E).4E). After Smad2 was knocked down for 72 hours, Snail expression was increased by 13-fold, and further increased by 24-fold after 2 hours TGF-β1 treatment (Figure (Figure4E).4E). In contrast, knockdown of Smad3 did not affect baseline Snail expression but significantly attenuated TGF-β1–induced Snail expression (Figure (Figure4E).4E). Knocking down Smad4 abrogated both baseline and TGF-β1–induced Snail expression (Figure (Figure4E).4E). Slug expression was also induced by TGF-β1 treatment, with a 2-fold increase 2 hours after TGF-β1 treatment (Figure (Figure4F).4F). However, none of the individual Smads affected Slug expression levels, with or without TGF-β1 treatment (Figure (Figure4F).4F). These data suggest that expression of Snail, but not Slug, is regulated by Smads. Thus, in vivo Slug overexpression in K5.Smad2–/– keratinocytes could be a secondary event.

Next, we assessed if Smad2 loss correlated to Snail overexpression in human skin SCCs. Overall, Snail overexpression and E-cadherin loss occurred at high frequencies in human skin SCCs. However, consistent with the association of Smad2 loss with poorly differentiated SCCs (Table (Table1),1), Smad2-negative SCCs (52 cases) exhibited a higher incidence of Snail overexpression than in 23 cases of Smad2-positive SCCs (90% vs. 73%; P < 0.05; Figure Figure5).5). Similarly, the rate of E-cadherin loss occurred in 79% of Smad2-negative SCCs versus 60% in Smad2-positive SCCs (P < 0.05; Figure Figure5). 5).

Figure 5
Human skin SCCs with Smad2 loss correlated with E-cadherin loss and nuclear Snail.

Elevated Snail contributed markedly to Smad2 loss–associated EMT.

Since the data from K5.Smad2–/– mice, human keratinocytes, and human skin SCCs revealed a correlation between Snail overexpression and Smad2 loss, we assessed whether increased Snail expression functionally contributed to Smad2 loss–associated EMT by knocking down Snail together with Smad2 in HaCaT cells (Figure (Figure6).6). In control keratinocytes, sporadic Snail nuclear staining cells were detected and E-cadherin stained the cell membrane. After 72 hours of Snail knockdown, Snail expression and protein was reduced by 80% (Supplemental Figure 8), and the number of Snail nuclear positive cells was markedly reduced (Figure (Figure6).6). E-cadherin staining in Snail siRNA–treated cells retained a similar pattern to control cells. After 72 hours of Smad2 knockdown, HaCaT cells lost the typical keratinocyte appearance, and some of them exhibited fibroblast-like morphology (Figure (Figure6),6), which correlated with increased Snail nuclear staining and loss of membrane-associated E-cadherin (Figure (Figure6).6). However, knocking down both Smad2 and Snail restored membrane-associated E-cadherin staining and epithelial morphology (Figure (Figure6),6), suggesting that Snail is the major target of Smad2 loss and contributes to Smad2 loss–associated EMT.

Figure 6
Snail contributed to Smad2 loss–associated EMT.

Enhanced Smad4 binding to the Snail promoter in Smad2-deficient keratinocytes.

To further analyze whether Snail overexpression induced by Smad2 loss was the result of enhanced transcriptional activity of Smad3 and/or Smad4, we performed in vivo chromatin immunoprecipitation (ChIP) for Smad binding to the Snail promoter in neonatal WT and Smad2–/– mouse skin. Within the TGF-β–regulatory region of the mouse Snail promoter, as identified by previous studies (9, 27), there are 2 SBEs at –438 bp and –1,077 bp upstream of the Snail transcriptional start site (TSS). We found that in WT skin, Smad2, -3, and -4 bound to both sites (Figure (Figure7,7, A and B) but not to intronic regions of the gene (data not shown). Quantitative PCR on the precipitated chromatin revealed that in Smad2–/– skin, Smad3 binding to both SBEs was at a capacity similar to that in WT skin (Figure (Figure7,7, A and B), suggesting that Smad2 does not affect the affinity of Smad3 binding to the Snail promoter. However, Smad4 binding to the Snail promoter increased by 8- and 29-fold on the –438-bp and the –1,077-bp sites, respectively, in K5.Smad2–/– skin compared with that in WT skin (Figure (Figure7,7, A and B). Therefore, these data suggest that normally, Smad2 either competes with, or impedes Smad4 binding to the SBE at the Smad3-binding site on the Snail promoter. To further assess if Smad2 loss–associated increase in Smad4 binding to the Snail promoter contributes to Snail overexpression, we knocked down Smad4 together with knockdown of Smad2. Knocking down Smad4 abrogated Smad2 loss–associated Snail overexpression (Figure (Figure7C),7C), suggesting that increased Smad4 binding contributed to transcriptional regulation of Snail in K5.Smad2–/– keratinocytes. Knockdown of Smad3 also abrogated Smad2 loss–associated Snail overexpression, suggesting that Smad3 binding in a complex with Smad4 is required for increased Snail transcription in Smad2-deficient keratinocytes.

Figure 7
Increased Smad3/Smad4-mediated Snail transcription contributes to Smad2 loss–associated Snail overexpression.


Smad2 and Smad4, but not Smad3, are frequently lost in human skin SCCs.

In the current study, we found that proteins of Smad2 or Smad4, but not Smad3, were frequently lost in human skin SCCs. In cases with LOH of Smad2 or Smad4, single-copy genetic loss may contribute to at least 50% loss of their transcripts and protein in each case, as mice with heterozygous deletion of Smad2 or Smad4 exhibited ~50% loss of transcripts and protein of these 2 molecules (see also ref. 28). Additionally, transcriptional and posttranslational modifications could contribute to further loss of the remaining Smad2 and Smad4 transcripts and protein. Several Smad ubiquitin-E3 ligases, which contribute to Smad protein degradation, have been identified, some of which have been shown to be overexpressed in cancer (2932). Thus, multiple mechanisms from the genetic to the posttranslational level could explain loss of Smad2 and Smad4 proteins, which are among the most frequent molecular alterations in skin cancer. Indeed, Smad2 and Smad4 loss occurs more frequently than the currently known common molecular alterations in human skin SCCs, e.g., oncogene ras activation or loss of the p53 tumor suppressor (33). Notably, the incidences of Smad2 and Smad4 loss in skin SCCs found in this study are much higher than in head and neck SCCs (34). These differences may reflect cancer etiology, which is largely attributed to UV irradiation in skin cancer and to tobacco carcinogen exposure in head and neck cancer.

Smad2 has a tumor suppressive effect on the skin.

Unlike keratinocyte-specific Smad4-knockout mice, which developed spontaneous skin SCCs, K5.Smad2–/– mice developed skin tumors neither spontaneously nor with TPA treatment alone (without DMBA initiation, data not shown), even though K5.Smad2–/– epidermis exhibited an increase in proliferation in response to TPA application. Thus, the increased proliferative potential of K5.Smad2–/– epidermis is insufficient as an initiator for skin carcinogenesis. This result is consistent with Smad2 expression patterns in human skin SCCs, in which Smad2 loss occurs only in SCCs but not in early stage actinic keratosis (25). Conversely, in the presence of a DMBA-induced H-ras mutation, a genetic alteration mimicking early stage human skin cancer (35), K5.Smad2–/– mice still did not develop skin tumors without TPA promotion (data not shown). Thus, Smad2 loss alone is also insufficient to promote initiated cells for cancer development. However, with both DMBA initiation and TPA promotion, K5.Smad2–/– mice were more susceptible to skin tumor formation and malignant conversion than WT mice. Although the current study limits the assessment of the true malignant conversion rate for each papilloma due to the necessity of euthanizing SCC-bearing mice with multiple papillomas, more K5.Smad2–/– mice developed SCCs at the same time points when compared with WT mice. Additionally, K5.Smad2–/– papillomas already harbored molecular changes seen in WT SCCs but not in papillomas, suggesting that the malignant progression program was in place prior to the pathological progression in K5.Smad2–/– tumors. Thus, Smad2 loss appears to cooperate with other molecular alterations elicited by the chemical carcinogenesis protocol to promote skin carcinogenesis. Interestingly, K5.Smad2+/– mice displayed tumor kinetics similar to K5.Smad2–/– mice. This observation is also consistent with a previous report that germline Smad2 heterozygous mice exhibited accelerated tumor formation and malignant progression in a skin chemical carcinogenesis experiment (16). These studies suggest a haploid insufficiency for Smad2 in tumor suppression.

Smad2 loss triggers molecular and pathological alterations associated with EMT.

Our current study reveals that in human skin cancer, Smad2 loss was associated with dedifferentiation, loss of E-cadherin, and Snail activation. Correlated with this observation, the accompanying animal study reveals that loss of Smad2 triggers pathological and molecular alterations associated with dedifferentiation and EMT started in nonlesional Smad2–/– epidermis. Among EMT associated genes, Snail overexpression appears to be a major target and mediator of Smad2 loss-induced EMT.

The effect of Smad2 loss on EMT is somewhat surprising given that TGF-β signaling is well documented to promote EMT via both Smad and non-Smad pathways (24). Unlike keratinocytes with knockdown of TGF-βRII, which overexpress TGF-β1 (25, 36), Smad2 loss did not cause increased TGF-β1. However, our data revealed a significant increase in promoter binding of Smad4 to the Snail promoter in Smad2–/– keratinocytes. It is possible that normally Smad2 either competes with or impedes the ability of Smad4 to bind Smad3 on the SBEs of the Snail promoter, therefore Smad2 loss confers more binding of Smad4 with Smad3. Although Smad2 has been shown to activate Snail, it is likely that Smad2 has a much weaker effect than Smad4, given the fact that Smad2, but not Smad4, normally recruits transcriptional corepressors to SBEs (2). Based on this, once Smad2 is lost, the corepressors would not be recruited to the SBEs, and Smad3 together with Smad4 would drive a higher level of Snail transcription. Supporting this explanation, knocking down either Smad3 or Smad4 abrogated Smad2 loss–associated Snail overexpression, and a previous study showed that the combination of Smad3 and Smad4 had the highest transcriptional activity on the Snail promoter (9). Our data also helps to explain the difference between our current finding and a previous finding showing that a dominant-negative form of either Smad2 or Smad3 blocked TGF-β1–induced EMT in skin SCC cells (8). In that study, either increased Smad4 binding to the Snail promoter or the loss of corepressors should not occur due to the presence of WT Smad2. Since Smad4–/– skin and early stage SCCs did not undergo EMT or exhibit the associated molecular alterations even in the presence of Smad2 and Smad3, Smad4 appears to be indispensable for EMT at least at early stages of skin carcinogenesis. Similar to our current finding, a previous study shows that pancreatic ductal adenocarcinomas derived from Smad4-null cells are more well differentiated and have less EMT in comparison with tumors with intact Smad4 (37). Consistently, Ju et al. (19) reported that in hepatocyte-specific Smad2-knockout mice, hepatocytes underwent de-differentiation and EMT, whereas Smad3–/– hepatocytes did not. Since Smad4 was not lost in Smad2–/– skin and in early stage tumor cells, enhanced Smad4 binding to the Snail promoter is likely the major contributor to increased Snail expression, at least at early stages of skin carcinogenesis in Smad2–/– mice. When Smad4 is lost at late stages, multiple genetic/epigenetic alterations accumulated in tumor epithelia could be sufficient to sustain EMT and invasion. To this end, other pathways commonly activated in late-stage skin carcinogenesis, e.g., AKT and NF-κB, have been shown to activate Snail expression and EMT (38, 39).

It is worthwhile to mention that accelerated EMT does not always contribute to malignant progression. For instance, Smad4–/– keratinocytes did not exhibit EMT but proceeded to become spontaneous SCCs (13, 14). Conversely, accelerated EMT in Smad2–/– keratinocytes was insufficient to cause spontaneous skin cancer formation. Thus, EMT would promote tumor invasion in vivo only when coupled with other oncogenic events. Further, all of the EMT-associated genes upregulated in K5.Smad2–/– tumors also have additional functions for promoting cancer invasion. For instance, Snail and Slug regulate cell survival and apoptosis (4044), and Snail overexpression in the epidermis causes keratinocyte hyperproliferation (45). Tenascin C has been implicated in angiogenesis (46). All these functions could contribute to accelerated tumor formation and progression K5.Smad2–/– mice.

In summary, we report that Smad2 and Smad4 are frequently lost in human skin SCCs. The LOH of Smad2 and Smad4 in human skin SCCs and the haploid insufficiency of Smad2 and Smad4 in mouse skin carcinogenesis (see also ref. 47) suggest that in human skin cancer, even if cancer lesions lose 1 allele of the Smad2 or Smad4 or reduce their proteins to less than 50%, these lesions may have lost the tumor suppressive effect of Smad2 or Smad4. On the other hand, our study also shows that Smad2 loss–associated increase in Smad4 binding to the Snail promoter beyond a physiological level facilitates Snail activation and EMT. Our study prompts future research into how loss of both Smad2 and Smad4 affects skin carcinogenesis in vivo. It also remains to be determined how Smad2 loss after tumor formation, as seen in human cancers, affects tumor differentiation and malignant progression.


Human skin SCC collection and sample preparation.

Human skin SCC and normal skin samples were from a human SCC tissue array (US Biomax) and were collected from surgically resected specimens between the years 2000 and 2005 from consenting patients at Oregon Health & Science University under an Institutional Review Board–approved protocol. The tissue array contained 75 SCCs and 4 normal skin samples graded by 2 pathologists from the vendor. We confirmed the grade for samples from both the tissue array and the ones we collected. In total, tissues used for IHC included 83 SCC cases and 10 normal skin samples. Tissues used for immunofluorescence included 75 SCC cases and 4 skin samples. Tissues used for quantitative RT-PCR (qRT-PCR) assays included 33 poorly differentiated skin SCCs and 6 normal skin samples. Among these, 21 samples that contained adjacent nonneoplastic skin in paraffin sections were microscopically dissected, and tissues scrapings from nonneoplastic skin and SCCs were collected separately. For LOH analysis, DNA from these tissue sections was extracted using the WaxFree DNA Paraffin Sample DNA extraction kit (TrimGen Inc.) and used for PCR, using primers for microsatellite repeat regions (48) (D18S555, forward 5′-FAM-GTGCGATGGCAAAATAGATG-3′, reverse 5′-ATTTTCTAGGAAAGAGCTAGC-3′; D18S1137, forward 5′-FAM-TGACTATTTGCACATCTGGC-3′, reverse 5′-GGACTTGCACGCTAATGAC-3′; D18S460, forward 5′-FAM-CTGAAGGGTCCTTGCC-3′, reverse 5′-GCCAGCCTTGGCAGTC-3′). PCR products were column purified (Wizard SV Gel and PCR Clean-Up System; Promega) and analyzed using fragment length polymorphism analysis (Applied Biosystems 3130xL and Peak Scanner Software, version 1.0). LOH was determined using the following formula: peak height of allele 1 of tumor divided by peak height of allele 2 of tumor, the result of which was divided by peak height of allele 1 of adjacent skin divided by peak height of allele 2 of adjacent skin, the result of which was greater than 1.5.

Tissue histology, tumor classification, and IHC.

Skin and tumor samples were fixed in 10% neutral-buffered formalin at 4°C overnight, embedded in paraffin, sectioned to 6 μm thickness, and stained with H&E. Tumor types were determined by H&E analysis, using the criteria described previously (49). IHC was performed on paraffin sections as we have previously described (25), using primary antibodies against human and mouse Smad2 (1:200; Zymed), Smad3 (1:100; Santa Cruz Biotechnology Inc.), and Smad4 (1:100; Santa Cruz Biotechnology Inc.). Sections were counterstained with hematoxylin.

Generation of inducible and keratinocyte-specific Smad2- and Smad4-knockout mice.

The K5.Cre*PR1, the Smad2f/f line, and Smad4f/f line were generated on a C57BL/6 background as previously reported (18, 19, 50). K5.Cre*PR1 mice were crossed with Smad2f/f or Smad4f/f mice to generate WT, K5.Smad2f/wt, K5.Smad2f/f, or K5.Smad4f/f genotypes. For genotyping, PCR using tail DNA was performed with primers specific for the floxed region and the Cre recombinase as previously reported (18, 19, 50). Cre-mediated Smad2 or Smad4 deletion in keratinocytes was achieved with topical application of RU486 (20 μg in 100 μl ethanol) once a day for 3–5 days at time points specified in the Results section. Smad2 or Smad4 gene deletion was detected by PCR performed on DNA extracted from RU486-treated skin, using deletion-specific primers (19, 50).

Skin chemical carcinogenesis protocol.

Eight-week-old mouse skin was shaved and topically treated with 20 μg of DMBA (dissolved in 50 μl acetone; Sigma-Aldrich). One week later, 5 μg of TPA (dissolved in 50 μl acetone; Sigma-Aldrich) was applied to skin twice a week for 20 weeks. In total, 20 Smad2+/+, 19 Smad2–/–, and 12 Smad2+/– mice, with equal distribution of genders in each group, were used in the carcinogenesis study (17).

RNA extraction and qRT-PCR.

RNA was isolated from human and mouse skin and tumors using RNAzol B (Tel-Test), as we have previously described (51), and purified using a QIAGEN RNeasy Mini kit (QIAGEN). The qRT-PCR was performed as we have previously described (52). Transcripts of human Smad2 and Smad4, mouse Smad2, K8, Snail, Slug, vimentin, tenascin C, and E-cadherin were examined using corresponding Taqman Assays-on-Demand probes (Applied Biosystems). A K14 or GAPDH RNA probe was used as an internal control. Three to nine samples from each genotype of mice or cultured cells were used for qRT-PCR. The mean expression level from K5.Smad2+/+ samples (unless otherwise specified) of each particular gene being analyzed was set as 1 arbitrary unit.

Double-stain immunofluorescence.

Double-stain immunofluorescence on paraffin-embedded tissue sections was performed as we have previously described (53). Each section was incubated overnight at 4°C with a primary antibody together with a guinea pig antiserum against mouse K14, the latter of which highlights the epithelial compartment of the skin (51). An Alexa Fluor 488–conjugated (green) secondary antibody against the species of the primary antibody (1:100–1:400; Molecular Probes) and Alexa Fluor 594–conjugated (red) anti–guinea pig secondary antibody (1:100; Molecular Probes) were used to visualize the staining. The primary antibodies included K1 (1:500; Covance), K8 (1:100; Fitzgerald), vimentin (1:200; Sigma-Aldrich), E-cadherin (1:100; BD Bioscience), K14 (1:400; Fitzgerald), Snail (1:200; Abcam), and αSMA (1:200; Sigma-Aldrich).

Quantitative chromatin immunoprecipitation.

Four mouse back skins from each group of WT and K5.Smad2–/– mice were homogenized on ice in 5 ml of 1% formalin and incubated at room temperature for 30 minutes after adding an additional 5 ml of 1% formalin to each tube. Each sample was then diluted in 1 ml of 10X Glycine Stop Solution (Active Motif), incubated at room temperature for 5 minutes, and then centrifuged at 1,400 g for 10 minutes at 4°C. The resulting pellet was used for ChIP Enzymatic Digestion following the manufacturer’s protocol (Active Motif). Antibodies, 3 μg/each, to Smad2 (Zymed), Smad3 (Upstate), and Smad4 (Upstate) were used to immunoprecipitate the sheared chromatin complexes. Rabbit IgG (3 μg; Santa Cruz Biotechnology Inc.) was used as a negative control for antibody specificity. DNA obtained from eluted beads was used for quantitative PCR using Power SYBR Green Master Mix (Applied Biosystems). Primers encompassing the SBE sites of the Snail promoter (Supplemental Table 1) were used for PCR. Positive binding was defined as antibody binding more than 10-fold of the IgG-negative control. Difference in Ct (ΔCt) values were obtained by normalizing IP Ct values to input values for each group. ΔΔCt values were obtained by comparing the ΔCt values of Smad2–/– skin to WT skin. Values are expressed as fold change based on ΔΔCt values.

HaCaT keratinocyte culture and siRNA knockdown.

HaCaT keratinocytes were cultured in DMEM with high levels of glucose with 10% FBS and penicillin-streptomycin antibiotics. Twenty-four hours prior to siRNA transfection, cells were switched to DMEM with low levels of glucose with 0.2% FBS and penicillin-streptomycin antibiotics. Cells were transfected with siRNAs for human Smad2, Smad3, Smad4, or Snail (Supplemental Table 2) using XtremeGene siRNA Transfection Reagent (Roche) in 6-well plates or chamber slides, at a final concentration of 50 pmol siRNA/μl in Optimem media (Gibco). Four hours posttransfection, media was switched to DMEM with high levels of glucose. Prior to cell harvest in culture dishes or fixation in the chamber slides, cells were treated with or without 10 pM TGF-β1 for period of times specified in the Results section. Cells were harvested at 48 or 72 hours after siRNA transfection for RNA extraction using Qiashredder and RNeasy kits (QIAGEN). Chamber slides were fixed for 40 minutes at room temperature in 2% paraformaldehyde and stained with antibodies specified in the Results section, using the methods as described above.


Significant differences between the values obtained in each assay on samples from various genotypes were determined using the Student’s t test and expressed as mean ± SEM, with the exception of evaluation of human SCCs and tumor malignancy, in which a χ2 test was used. P values of less than 0.05 were considered significant.

Supplementary Material

Supplemental data:


The authors thank Qinghong Zhang and Jiri Zavadil for suggestions for the experiments. We would also like to thank an anonymous donation to our research related to this publication. This work was supported by NIH grants to X.-J. Wang. K.E. Hoot and J. Lighthall are recipients of NIH training grants.


Nonstandard abbreviations used: DMBA, dimethylbenz[α]anthracene; EMT, epithelial-mesenchymal transition; IHC, immunohistochemistry; K5, keratin 5; K5.Cre*PR1, mutant Cre recombinase fused to a truncated progesterone receptor targeted by K5 promoter; LOH, loss of heterozygosity; qRT-PCR, quantitative RT-PCR; SBE, Smad-binding element; SCC, squamous cell carcinoma; TPA, 12-O-tetradecanoyl-phorbol-13-acetate.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J. Clin. Invest. 118:2722–2732 (2008). doi:10.1172/JCI33713

Xiao-Jing Wang’s present address is: Portland VA Cancer Center, Portland, Oregon, USA.


1. Massagué J., Seoane J., Wotton D. Smad transcription factors. Genes Dev. 2005;19:2783–2810. doi: 10.1101/gad.1350705. [PubMed] [Cross Ref]
2. Massague J., Gomis R.R. The logic of TGFbeta signaling. FEBS Lett. 2006;580:2811–2820. doi: 10.1016/j.febslet.2006.04.033. [PubMed] [Cross Ref]
3. Brown K.A., Pietenpol J.A., Moses H.L. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGFβ signaling. . J. Cell. Biochem. 2007;101:9–33. doi: 10.1002/jcb.21255. [PubMed] [Cross Ref]
4. Nomura M., Li E. Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature. 1998;393:786–790. doi: 10.1038/31693. [PubMed] [Cross Ref]
5. Yang X., Li C., Xu X., Deng C. The tumor suppressor SMAD4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice. Proc. Natl. Acad. Sci. U. S. A. 1998;95:3667–3672. doi: 10.1073/pnas.95.7.3667. [PubMed] [Cross Ref]
6. Yang X., et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J. 1999;18:1280–1291. doi: 10.1093/emboj/18.5.1280. [PubMed] [Cross Ref]
7. Bierie B., Moses H.L. TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer. 2006;6:506–520. doi: 10.1038/nrc1926. [PubMed] [Cross Ref]
8. Oft M., Akhurst R.J., Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat. Cell Biol. 2002;4:487–494. [PubMed]
9. Cho H.J., Baek K.E., Saika S., Jeong M.J., Yoo J. Snail is require for transforming growth factor-beta-induced epithelial-mesenchymal transition by activating PI3 kinase/Akt signal pathway. Biochem. Biophys. Res. Commun. 2007;353:337–343. doi: 10.1016/j.bbrc.2006.12.035. [PubMed] [Cross Ref]
10. Ten Dijke P., Goumans M.J., Itoh F., Itoh S. Regulation of cell proliferation by Smad proteins. J Cell. Physiol. 2002;191:1–16. doi: 10.1002/jcp.10066. [PubMed] [Cross Ref]
11. Sjoblom T., et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314:268–274. doi: 10.1126/science.1133427. [PubMed] [Cross Ref]
12. Wolfraim L.A., et al. Loss of Smad3 in acute T-cell lymphoblastic leukemia. N. Engl. J. Med. 2004;351:552–559. doi: 10.1056/NEJMoa031197. [PubMed] [Cross Ref]
13. Yang L., et al. Targeted disruption of Smad4 in mouse epidermis results in failure of hair follicle cycling and formation of skin tumors. Cancer Res. 2005;65:8671–8678. doi: 10.1158/0008-5472.CAN-05-0800. [PubMed] [Cross Ref]
14. Qiao W., et al. Hair follicle defects and squamous cell carcinoma formation in Smad4 conditional knockout mouse skin. Oncogene. 2006;25:207–217. [PubMed]
15. Vijayachandra K., Lee J., Glick A.B. Smad3 regulates senescence and malignant conversion in a mouse multistage skin carcinogenesis model. Cancer Res. 2003;63:3447–3452. [PubMed]
16. Tannehill-Gregg S.H., Kusewitt D.F., Rosol T.J., Weinstein M. The roles of Smad2 and Smad3 in the development of chemically induced skin tumors in mice. Vet. Pathol. 2004;41:278–282. doi: 10.1354/vp.41-3-278. [PubMed] [Cross Ref]
17. Li A.G., Lu S.L., Zhang M.X., Deng C., Wang X.J. Smad3 knockout mice exhibit a resistance to skin chemical carcinogenesis. Cancer Res. 2004;64:7836–7845. doi: 10.1158/0008-5472.CAN-04-1331. [PubMed] [Cross Ref]
18. Caulin C., et al. Inducible activation of oncogenic K-ras results in tumor formation in the oral cavity. Cancer Res. 2004;64:5054–5058. doi: 10.1158/0008-5472.CAN-04-1488. [PubMed] [Cross Ref]
19. Ju W., et al. Deletion of Smad2 in mouse liver reveals novel functions in hepatocyte growth and differentiation. Mol. Cell. Biol. 2006;26:654–667. doi: 10.1128/MCB.26.2.654-667.2006. [PMC free article] [PubMed] [Cross Ref]
20. Rugg E.L., Leigh I.M. The keratins and their disorders. Am. J. Med. Genet. C Semin. Med. Genet. 2004;131C:4–11. doi: 10.1002/ajmg.c.30029. [PubMed] [Cross Ref]
21. Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 2005;17:548–558. doi: 10.1016/ [PubMed] [Cross Ref]
22. Hendrix M.J., Seftor E.A., Seftor R.E., Trevor K.T. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am. J. Pathol. 1997;150:483–495. [PubMed]
23. Masszi A., et al. Central role for Rho in TGF-beta1-induced alpha-smooth muscle actin expression during epithelial-mesenchymal transition. Am. J. Physiol. Renal Physiol. 2003;284:F911–F924. [PubMed]
24. Zavadil J., Bottinger E.P. TGFbeta and epithelial-to-mesenchymal transitions. Oncogene. 2005;24:5764–6774. doi: 10.1038/sj.onc.1208927. [PubMed] [Cross Ref]
25. Han G., et al. Distinct mechanisms of TGF-b1–mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. . J. Clin. Invest. 2005;115:1714–1723. doi: 10.1172/JCI24399. [PubMed] [Cross Ref]
26. He W., Cao T., Smith D.A., Myers T.E., Wang X.J. Smads mediate signaling of the TGFbeta superfamily in normal keratinocytes but are lost during skin chemical carcinogenesis. Oncogene. 2001;20:471–483. doi: 10.1038/sj.onc.1204117. [PubMed] [Cross Ref]
27. Peinado H., Quintanilla M., Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines. J. Biol. Chem. 2003;278:21113–21123. doi: 10.1074/jbc.M211304200. [PubMed] [Cross Ref]
28. Lüttges J., et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am. J. Pathol. 2001;158:1677–1683. [PubMed]
29. Kavsak P., et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGFb receptor for degradation. Mol. Cell. 2000;6:1365–1375. doi: 10.1016/S1097-2765(00)00134-9. [PubMed] [Cross Ref]
30. Lin X., Liang M., Feng X.H. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J. Biol. Chem. 2000;275:36818–36822. doi: 10.1074/jbc.C000580200. [PubMed] [Cross Ref]
31. Wan M., et al. Smad4 protein stability is regulated by ubiquitin ligase SCF beta-TrCP1. J. Biol. Chem. 2004;279:14484–14487. doi: 10.1074/jbc.C400005200. [PubMed] [Cross Ref]
32. Liang M., et al. Ubiquitination and proteo­lysis of cancer-derived Smad4 mutants by SCFSkp2. Mol. Cell. Biol. 2004;24:7524–7537. doi: 10.1128/MCB.24.17.7524-7537.2004. [PMC free article] [PubMed] [Cross Ref]
33. Dlugosz A., Merlino G., Yuspa S.H. Progress in cutaneous cancer research. J. Investig. Dermatol. Symp. Proc. 2002;7:17–26. doi: 10.1046/j.1523-1747.2002.19631.x. [PubMed] [Cross Ref]
34. Xie W., et al. Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis. Oncol. Res. 2003;14:61–73. [PubMed]
35. Corominas M., et al. ras activation in human tumors and in animal model systems. Environ. Health Perspect. 1991;93:19–25. doi: 10.2307/3431163. [PMC free article] [PubMed] [Cross Ref]
36. Lu S.L., et al. Loss of transforming growth factor b type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev. 2006;20:1331–1342. doi: 10.1101/gad.1413306. [PubMed] [Cross Ref]
37. Bardeesy N., et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006;20:3130–3146. doi: 10.1101/gad.1478706. [PubMed] [Cross Ref]
38. Dong R., et al. Role of nuclear factor kappa B and reactive oxygen species in the tumor necrosis factor-a-induced epithelial-mesenchymal transition of MCF-7 cells. Braz. J. Med. Biol. Res. 2007;40:1071–1078. [PubMed]
39. Lester R.D., Jo M., Montel V., Takimoto S., Gonias S.L. uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J. Cell Biol. 2007;178:425–436. doi: 10.1083/jcb.200701092. [PMC free article] [PubMed] [Cross Ref]
40. Zha Y., He J., Mei Y., Yin T., Mao L. Zinc-finger transcription factor Snail accelerates survival, migration, and expression of matrix metalloproteinase-2 in human bone mesenchymal stem cells. Cell Biol. Int. 2007;31:1089–1096. doi: 10.1016/j.cellbi.2007.03.023. [PubMed] [Cross Ref]
41. Peinado H., Olmeda D., Cano A. Snail, ZEB, and bHLH factors in tumor progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer. 2007;7:415–428. doi: 10.1038/nrc2131. [PubMed] [Cross Ref]
42. Papadavid E., Pignatelli M., Zakynthinos S., Krausz T., Chu A.C. Abnormal immunoreactivity of the E-cadherin/catenin (a-, b-, and g-) complex in premalignant and malignant non-melanocytic skin tumours. J. Pathol. 2002;196:154–162. doi: 10.1002/path.1019. [PubMed] [Cross Ref]
43. Wu W.S., et al. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. . Cell. 2005;123:641–653. doi: 10.1016/j.cell.2005.09.029. [PubMed] [Cross Ref]
44. Craene B.D., vanRoy F., Berx G. Unraveling signalling cascades for the Snail family of transcription factors. Cell Signal. 2005;17:535–547. doi: 10.1016/j.cellsig.2004.10.011. [PubMed] [Cross Ref]
45. Jamora C., et al. A signaling pathway involving TGF-beta2 and snail in hair follicle morphogenesis. PLoS Biol. 2005;3:e11. [PMC free article] [PubMed]
46. Ballard V.L., et al. Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularization. FASEB J. 2006;20:717–719. [PubMed]
47. Teng Y., et al. Synergistic function of Smad4 and PTEN in suppressing forestomach squamous cell carcinoma in the mouse. Cancer Res. 2006;66:6972–6981. doi: 10.1158/0008-5472.CAN-06-0507. [PubMed] [Cross Ref]
48. Toda T., et al. Analysis of microsatellite instability and loss of heterozygosity in uterine endometrial adenocarcinoma. Cancer Genet. Cytogenet. 2001;126:120–127. doi: 10.1016/S0165-4608(00)00400-3. [PubMed] [Cross Ref]
49. Aldaz C.M., Conti C.J., Klein-Szanto A.J., Slaga T.J. Progressive dysplasia and aneuploidy are hallmarks of mouse skin papillomas: relevance to malignancy. Proc. Natl. Acad. Sci. U. S. A. 1987;84:2029–2032. doi: 10.1073/pnas.84.7.2029. [PubMed] [Cross Ref]
50. Yang X., Li C., Herrera P.L., Deng C.X. Generation of Smad4/Dpc4 conditional knockout mice. Genesis. 2002;32:80–81. doi: 10.1002/gene.10029. [PubMed] [Cross Ref]
51. Wang X.J., Greenhalgh D.A., Lu X.R., Bickenbach J.R., Roop D.R. TGF alpha and v-fos cooperation in transgenic mouse epidermis induces aberrant keratinocyte differentiation and stable, autonomous papillomas. Oncogene. 1995;10:279–289. [PubMed]
52. Lu S.L., et al. Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res. 2004;64:4405–4410. doi: 10.1158/0008-5472.CAN-04-1032. [PubMed] [Cross Ref]
53. Li A.G., Wang D., Feng X.H., Wang X.J. Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. EMBO J. 2004;23:1770–1781. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation